Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever
brief summary
The primary objective is to evaluate the main pharmacokinetic (PK) parameters, efficacy, and safety of goflikicept (GFC) in children and adolescents with colchicine-resistant or colchicine-intolerant familial Mediterranean fever (FMF).
detailed description
This is an open-label, non-randomized clinical study in pediatric and adolescent participants.
The study consists of three periods:
* the screening period (up to 12 weeks) which includes a period for evaluating eligibility criteria and monitoring "marker" attacks * treatment period, up to 56 weeks including:
* 16-week main treatment period * 40-week long-term treatment period * 8-week safety follow-up
The total maximum duration of participation of one participant in the study is up to 76 weeks, i.e. approximately 1 year and 6 months.
The study enrolls participants in two sequential cohorts. Cohort 1 includes 6 adolescents aged 12-14 years in the Kingdom of Saudi Arabia (KSA) and 12-17 years in other countries. An interim safety and pharmacokinetic (PK) analysis will be performed. If enrollment of participants aged 5-17 years is considered feasible, Cohort 2 enrolls participants aged 5-14 years in the KSA and 5-17 years in other countries, until at least 18 participants receive the investigational treatment.
official title
International, Multicenter, Open-label Clinical Study of Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Participants With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine